Welcome to our dedicated page for Tourmaline Bio news (Ticker: TRML), a resource for investors and traders seeking the latest updates and insights on Tourmaline Bio stock.
Tourmaline Bio, Inc. (TRML) generated a steady flow of news as a late-stage clinical biotechnology company focused on immune and inflammatory diseases, particularly cardiovascular inflammation and thyroid eye disease. Company press releases emphasize its lead asset, pacibekitug (TOUR006), a long-acting, fully human, anti-IL-6 monoclonal antibody being evaluated across multiple indications.
News items for TRML prominently feature updates on the Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease. These include announcements of over-enrollment, timing of topline data, and detailed topline and follow-up results describing rapid, deep, and durable hs-CRP reductions and pharmacodynamic effects on biomarkers such as lipoprotein(a), fibrinogen, and serum amyloid A. Additional releases cover plans for a potential Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease (ASCVD) and a Phase 2 proof-of-concept trial in abdominal aortic aneurysm (AAA).
Tourmaline’s news flow also covers its Phase 2b spiriTED trial in thyroid eye disease, scientific publications and conference presentations related to IL-6 signaling and cardiovascular and ophthalmic disease, and corporate events such as participation in investor conferences and the strengthening of its Cardiovascular Scientific Advisory Board.
A major development in the TRML news stream is the announcement of an Agreement and Plan of Merger with Novartis AG, under which a Novartis subsidiary launched a cash tender offer to acquire all outstanding Tourmaline shares. Subsequent communications and SEC filings report the completion of the tender offer, the closing of the merger, and the resulting change in control and delisting of TRML from the Nasdaq Global Select Market.
Investors and observers using this news page can review historical press releases and related disclosures to understand Tourmaline’s clinical progress with pacibekitug, its scientific positioning around IL-6–driven inflammation, and the sequence of events that led to its acquisition by Novartis and transition from a public to a privately held subsidiary.
Tourmaline Bio announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Robinson has been with Tourmaline since last summer and has served as the Interim CFO and Treasurer since October 2023. He played a key role in Tourmaline's growth, including a reverse merger in October 2023 and a $172.5 million public offering in January 2024. Robinson brings nearly 15 years of biotech finance and operations experience, having worked at Korro Bio, Jounce Therapeutics, and Merrimack Pharmaceuticals. He holds a B.S. in Management and an M.S. in Accounting from Boston College and is a CPA.
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company, announced that its CEO, Sandeep Kulkarni, will present at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for Thursday, June 6, 2024, at 2:30 pm ET. A live webcast and replay will be available on the Tourmaline Bio website.
Tourmaline Bio has dosed the first patient in its Phase 2 TRANQUILITY trial for TOUR006, a monoclonal antibody targeting IL-6 to treat atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular conditions. This randomized, double-blind, placebo-controlled trial involves patients with high inflammatory risk and chronic kidney disease. The trial aims to assess the drug's safety, pharmacokinetics, and pharmacodynamics, with results anticipated in the first half of 2025. If successful, TOUR006 could advance to Phase 3 by 2025, offering quarterly subcutaneous dosing and potentially positioning itself as a best-in-class treatment for ASCVD and related conditions.
Tourmaline Bio, Inc. reported its Q1 2024 financial results and recent business highlights. Initiatives include a Phase 2 trial for ASCVD and TED, a successful public offering, and $350.3 million in cash reserves. The company aims to improve the lives of patients with immune and inflammatory diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Tourmaline Bio (TRML)?
What is the market cap of Tourmaline Bio (TRML)?
